USFDA determines inspection classification of 'Voluntary Action Indicated' for the Solid dosage manufacturing facility at Roorkee, India

Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Pharma Limited, today announced that its subsidiary Jubilant Generics Limited ('JGL') received a communication from the USFDA through which the regulatory agency intimated that pursuant to its January 25 to February 2, 2024 audit of JGL's Solid dosage manufacturing facility at Roorkee, India, it has determined the inspection classification of the facility as "Voluntary Action Indicated (VAI)".

Based on this inspection and the USFDA VAI classification, the facility is considered to be in acceptable state of compliance with regard to current good manufacturing practices (cGMP). With this, the FDA has concluded that this inspection is "closed".

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 665.65 as compared to the previous close of Rs. 701.65. The total number of shares traded during the day was 67295 in over 4007 trades.

The stock hit an intraday high of Rs. 699.65 and intraday low of 658.90. The net turnover during the day was Rs. 45678036.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 JubilantPharma JubilantGenerics Roorkee India USFDA VAI